Compare Abeona Therapeutics Inc (ABEO) vs Twilio Inc (TWLO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Twilio Inc — how do they compare? Abeona Therapeutics Inc trades at $6.75 (market cap $373.32M), while Twilio Inc trades at $212.65 (market cap $32.17B). The key difference: Twilio Inc is far larger — about 86.2× Abeona Therapeutics Inc's market cap. Which is the better fit depends on your goals.
| ABEO | TWLO | |
|---|---|---|
Market Cap | $373.32M | $32.17B |
Sector | Health | Technology |
52-Week High | $7.23 | $236.64 |
52-Week Low | $4.17 | $92.44 |
Enterprise Value | $228.22M | $30.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Twilio (TWLO) trades at $211.97, up 1.27% with bullish technical signals and strong analyst support. The stock shows improving fundamentals with revenue growth from $4.5B to $5.1B in 2025 and a return to profitability after years of losses. Recent earnings beats and AI-driven demand for cloud communications tools support positive momentum. Technical indicators show the stock trading near pivot point resistance at $210 with bullish moving average alignment.
Twilio presents a growth opportunity with margin expansion potential and AI adoption driving demand, though elevated valuation metrics (P/E 316.79) warrant caution. Key risks include competitive pressures in cloud communications and execution challenges in maintaining profitability growth. Analyst consensus remains strongly bullish with 75% buy ratings and $211.69 price target, suggesting balanced risk-reward near current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Twilio Inc
Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →
